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ABSTRACT
The history of health insurance in the United States has perpetuated and enabled a
health care industry that has been rewarded for increased spending rather than cost
control. With the original plan setting no spending limit on health care providers, fee-forservice reimbursement provided greater incentive to spend than to contain costs.
Attempts to control the soaring costs of health care services have given rise to managed
care insurance plans that base reimbursement on health outcome data. Given that the
birth of managed care includes stringent reimbursement guidelines and ensuing
controversy over services provided or not provided, this study sought to determine if
differences in quality of care existed between two common types of health insurance, feefor-service (FFS) and health maintenance organization (HMO) insurance plans for the
most costly chronic illness, congestive heart failure (CHF). Utilizing primary and
secondary data obtained from an ongoing CHF study at the University of Tennessee
Medical Center in Knoxville, Tennessee, this study compared CHF health outcomes
between FFS and HMO insurance plans.
With an N of 154 cases, results revealed 0.37 of a day shorter length of stay in HMO
members with an average of 4.95 and 5.32 days for HMO & FFS members respectively.
In addition, HMO members displayed higher readmission rates with 25.6% of HMO
members and 22.6% of FFS members readmitted to the hospital within 30 days of
discharge with a related diagnosis. For the previously stated outcomes, no statistically
significant difference was found between the insurance plans. Other findings included all
six cases of mortality found in FFS insurance plans, however an exposed odds ratio test
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did not indicate a statistically significant difference in mortality rates due to sample size
and distribution. All six cases of mortality were found in patients ages 67 and up with an
association between being age 67+ and enrolled in a FFS insurance plan.
Recommendations for future research include further study into length of stay and the
possible effect on readmission rates for members of HMO insurance plans. Investigation
into documentation of teaching, follow-up scheduled at discharge, and the effect on
readmission rates could provide data supporting the need for adequate teaching and
follow up to decrease exacerbations and subsequent higher readmission rates.
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CHAPTER I
INTRODUCTION
This chapter covers the following topics: introductory background, the need for the
study, the statement of the problem, research questions, basic assumptions, delimitations,
limitations, and definitions. This section provides a brief overview of the history of
health insurance in the United States, including the emergence of managed care and the
need for objective studies measuring the quality of care in managed care insurance plans.

NEED FOR THE STUDY
The history of health insurance in the United States has perpetuated and enabled a
health care industry that has been rewarded for increased spending rather than cost
control. With the original plan setting no spending limit on health care providers, fee-forservice reimbursement provided greater incentive to spend than to contain costs.
Attempts to control the soaring costs of health care services have given rise to managed
care insurance plans that base reimbursement on health outcome data. Given that the
birth of managed care includes stringent reimbursement guidelines and ensuing
controversy over services provided or not provided, studies are needed to compare the
quality of care provided by managed care insurance plans to the traditional method of
health insurance, Fee-For-Service (FFS) cost reimbursement. In the sections below, the
demise of the fee-for-service system and need for health care reform including managed
care is discussed.
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Evolution of Health Care Industry Reimbursement
Although the rate of increase has slowed in the past few years, the cost of health care
services in the United States (U.S.) adjusted in real dollars has continued to exceed the
national rate of inflation for several decades (Getzen, 2000). Attempts to reform the
current system have left legislators, committee members, and health care professionals
exhausted and most unfortunately, back at the drawing table. In 1965, the introduction of
Medicare and Medicaid provided the healthcare industry with greater financial resources
from federal and state government funds. Unbeknownst to policy makers at the time, a
fee-for-service sleeping giant was created that transformed the health care industry into a
capitalistic, major money-making industry driven by dollars and cents. Decades later, as
our nation ails in financial distress from the burden of attempting to finance health care
services for its citizens, we have awakened to the realization that perhaps the initial plan
did not include considerable foresight. In accordance with the old adage...if your outgo
exceeds your income, then your upkeep will be your downfall...the United States
government took drastic measures in the 1980s when they instituted Diagnosis-Related
Groups (DRGs) to help control the escalating costs of the fee-for-service industry that
had been created.
Given the undisputed point that the health care system needed to be reformed due to
the United States Government spending far too great a portion of the Gross Domestic
Product (GDP) on health care services through Medicare and Medicaid expenditures, the
birth of managed care sought to manage costs and ease the burden of financing health
care services for the U.S. government as well as commercial insurance providers. The
advent of Health Maintenance Organizations (HMOs) brought about decreased health
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care expenditures by managing costs, but also raised a very important question: has the
quality of care decreased along with costs? Members enrolled in HMOs receive varying
benefits compared to members enrolled in FFS (also known as traditional) insurance
plans. The question has been raised that HMO members receive a different, possibly
decreased quality of care compared to members of traditional FFS insurance plans. The
foundation of managed care contract negotiations and the most reliable method to
measure the quality of care is to evaluate patient (health) outcomes. Patient outcome
measurements investigate the outcome of disease interventions and compare the benefit
or lack of benefit of various therapeutic measures.
Treatments prescribed by physicians are often predetermined by insurance coverage,
with some treatments being the bridge between life and death. Due to costs of expensive
therapies insurance companies, and especially HMOs, provide certain therapies after
greater scrutiny than has been provided for less expensive treatments. The Agency for
Healthcare Research and Quality (formerly the Agency for Health Care Policy and
Research) has led the way to Patient Outcome Research Teams (PORTs) whose purpose
is to fund multidisciplinary teams of investigators to identify effective care for a variety
of common medical and surgical health problems (Hickey et al, 1996). The goal is to
disseminate the findings to the community to aid in the development of standards of care,
the foundation of patient outcome measurement.
Tennessee has taken drastic measures to control escalating costs with the
implementation of TennCare in January of 1994. In an attempt to contain excessive
Medicaid expenditures, the state sought to introduce managed care to the Tennessee
health care industry. With the growth of managed care in Tennessee, there is a need for
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health outcome studies in the state of Tennessee comparing the quality of care between
managed care plans and the previous traditional fee-for-service method of
reimbursement.
Effects of Congestive Heart Failure on the Health Care Industry
Whether on a local, regional, or national level congestive heart failure health
outcomes are of concern to all health care providers given the seriousness and prevalence
of this chronic, debilitating illness. The prevalence of CHF in the United States is
approximately 4.7 million cases with an overall 5-year mortality rate of 50% (Whellan et
al, 1999). The economic burden of the illness is monumental. Xuan et al (2000)
conducted a retrospective study reviewing data from medical and pharmacy claims for
CHF patients to examine the economic burden and treatment patterns for the illness in a
managed care population. They report $20.2 billion spent on CHF in the United States in
1998 alone and conclude that improved management of the condition is needed to reduce
morbidity and associated treatment costs. Hospitalization has been concluded as the
greatest source of economic burden. Given half of the patients discharged with a CHF
diagnosis return to the hospital within 90 days, revealing the difficulty in managing the
condition, the economic burden could be eased by instituting better case management of
CHF patients (Xuan et al, 2000). Mackowiak (1998) recommended using a model to
determine concentration of costs for a CHF population. By separating costs by the type
of service or treatment utilized within a population, data specific to a population can be
generated. In addition, information on the impact of various treatment strategies can be
ascertained.
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To validate the need for measurement of congestive heart failure health outcomes in
East Tennessee, one only has to look at the prevalence and seriousness of the illness, as
well the obvious deficiency in the literature. The leading cause of death in the state of
Tennessee in 1997 was diseases of the heart, 308/100,000, with East Tennessee's
prevalence rate higher than the state average, 312/100,000 (NAPHSIS, 1997). Given that
the leading cause of death in the state of Tennessee was diseases of the heart and East
Tennessee's prevalence is higher than the state average (NAPHSIS, 1997), more heart
related studies leading to increased accountability of insurance plans to the quality of care
they provide are needed.
Tennessee statewide health outcome studies were found comparing TennCare
managed care plans by managed care organization as well as studies comparing managed
care plans to fee-for-service insurance plans (discussed in detail in Chapter 2). Studies
comparing health outcomes by insurance plan specific for congestive heart failure in the
state of Tennessee could not be found. The need for health outcome studies comparing
the quality of care for post-hospitalized congestive heart failure patients by insurance
plan is evidenced by the deficiency of published studies in the literature review. There
were no documented studies specific to measuring post-hospitalized congestive heart
failure health outcomes by insurance plan in East Tennessee. Of the limited number of
East Tennessee health outcome studies comparing outcomes by insurance plan, two were
found that evaluated perinatal outcomes following the implementation of TennCare in
1994. Cooper et al (1999) compared perinatal outcomes among the managed care
organizations providing care to TennCare enrollees. The appropriately designed study
utilizing retrospective cohort analysis revealed varying mortality rates among the
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managed care plans, but did not compare the rates to Tennessee's prior fee-for-service
method of reimbursement. Utilizing the same design, Ray et al (1998) compared
perinatal outcomes for TennCare enrollees to the previous Medicaid fee-for-service
method of reimbursement. Their study revealed no changes in perinatal outcomes
following the implementation of TennCare. In another appropriately designed
retrospective study utilizing secondary survey data to calculate the effects of TennCare
on utilization and outcomes, Sloan et al (2000) performed multivariate analysis to
compare the care of patients hospitalized for acute myocardial infarction between
TennCare and private insurance plans. Their study found no significant difference in the
outcomes for TennCare and private insurance enrollees.
Nationally, studies supporting the need for further CHF outcome comparisons by
insurance plan include Philbin et al (1998) who investigated the influence of payer status
on the process of care and resource utilization among patients hospitalized for CHF in the
New York State hospital system. Their retrospective study reported shorter length of stay
and lower hospital charges for HMO patients, taking into account that fewer days
hospitalized decreased total charges. In addition, they found Medicaid patients had
longest length of stay, greatest hospital charges, and highest CHF readmission rate.
Zannad et al (1999) further support the need for CHF studies given the prevalence of the
illness and deficiency of recent epidemiological studies taking into account modern
medical advances used in the treatment and management of patients with advanced CHF.
An appropriately designed retrospective study conducted in Oregon by Hanyu et al
(1998) utilized hospital discharge data to compare outcomes of care by insurance plan for
elderly CHF patients discharged from the hospital in 1995. They reported no short-term
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outcome differences among the varying insurance plans but suggested further attention be
given to the increased use of emergency departments by managed care patients.

STATEMENT OF THE PROBLEM
The problem addressed in this study determined differences in quality of care as
evidenced by post-hospitalized congestive heart failure health outcomes between FFS and
HMO insurance plans.

RESEARCH QUESTIONS
In order to address the afore stated purpose of the study, the following research
questions were developed:
Research Question #1:

How do comparable health outcomes differ for posthospitalized congestive heart failure patients enrolled in
FFS and HMO insurance plans?

Research Question #2:

How do health outcome measurements for posthospitalized congestive heart failure patients enrolled in
FFS and HMO insurance plans affect comparable
morbidity rates?

Research Question #3:

How do health outcome measurements for posthospitalized congestive heart failure patients enrolled in
FFS and HMO insurance plans affect comparable mortality
rates?
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ASSUMPTIONS
The following basic assumption regarding the investigation is as follows:
1. The secondary data provided was originally obtained using a valid and reliable
instrument and appropriate methodology.

DELIMITATIONS
For the purpose of this study the following delimitation was made:
1. This study was delimited to patients discharged from the University of
Tennessee Medical Center, Knoxville, with a diagnosis of congestive heart
failure enrolled in either a FFS or HMO insurance plan.

LIMITATIONS
For the purpose of this study, the following limitation was made:
1. Due to the population being limited to post-hospitalized congestive heart
failure patients in an East Tennessee health system, the generalizability of the
findings will be limited to the patient population and geographical area from
which the sample was selected.

DEFINITIONS
For the purpose of this study the following definitions were developed:
Centers for Medicare and Medicaid Services (CMS):

Formerly known as the

Health Care Financing Administration (HCFA), the CMS is a federal agency within the
U.S. Department of Health and Human Services that is responsible for running the
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Medicare and Medicaid programs. In collaboration with the Health Resources and
Services Administration, CMS is also responsible for the State Children's Health
Insurance Program (SCHIP).
Fee-for-service insurance plan:

A health insurance plan that reimburses providers a

prearranged amount for specified treatments when billed for those treatments with little
or no limitations on treatment set by the insurance provider.
Health Care Financing Administration:

Now known as the Centers for Medicare and

Medicaid Services (CMS). See CMS for definition.
Health maintenance organization insurance plan:

A health insurance plan that

provides and/or reimburses health care services based on predetermined outcome criteria
and manages each enrollee's care based on that criterion. The focus of care is on
prevention of disease.
Managed care:

A method of financing and administration of health services based

on supervision of health care with a focus on prevention of disease.
Medicare:

A health insurance benefit provided by the United States government to

qualified elderly and disabled citizens. The Medicare Part A benefit is managed by the
Centers for Medicare and Medicaid Services and is funded by taxpayer dollars.
Post-hospitalized congestive heart failure health outcomes:

Congestive heart

failure is a cardiovascular disease condition secondary to the heart's inability to
sufficiently pump the blood throughout the body; characterized by weakness,
breathlessness, and edema usually found in the lower extremities secondary to venous
stasis. The health outcomes measured for this study included the following:
1.

Average length of stay (days)
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2.

Mortality

3.

Gender (male/female)

4.

Payor (FFS/HMO)

5.

Readmitted within 30 days of discharge with related condition

6.

Attending physician (cardiology, medicine, family practice, other)

7.

Treated with ACE inhibitor

8.

Follow-up with a health care provider within 2 weeks scheduled at discharge

9.

Documentation of teaching (discharge instructions)
A.

Diet

B.

Weight

C.

Medications

D.

Activity level

E.

CHF teaching booklet

Quality of care:

Quality of care is the value and/or quality of medical care provided

to patients by health care providers, hospitals, and other health related services, most
often measured by health outcomes. For the purpose of this study, the quality of care is
measured by the post-hospitalization congestive heart failure health outcomes described
above.

SUMMARY
In conclusion, the need for further studies comparing health outcome measures
between FFS and HMO insurance plans is needed to maintain adequate quality of care. If
left unquantified and unreported, quality of medical care will be determined fiscally by
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pecuniary interested accountants and chief executive officers (CEOs) of large insurance
companies rather than the health care providers. The goal of this study is to provide
health outcome results by insurance plan, thereby increasing accountability of those plans
to its enrollees.

ORGANIZATION OF THE STUDY
The following sections will include the literature review, methodology, results of the
study, and conclusions.
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CHAPTER II
REVIEW OF LITERATURE
INTRODUCTION
The purpose of this chapter was to review research and literature findings related to
measurement of health outcome variations based on insurance status, specifically those
comparing FFS and HMO insurance plans, in addition to those studies utilizing
secondary data to further analyze health outcomes. The studies reviewed reported
primarily on secondary health outcome data obtained from large databases, from
secondary hospital data, or data obtained by managed care organizations for fee schedule
and length of stay research. Evidence based medicine (EBM) was incorporated into the
literature review process to provide a framework for establishing validity. A brief section
below defines the role of EBM in this study with subsequent sections reporting the
literature findings based on content, methodology, and content and methodology
combined.
Evidence Based Medicine and Review of Observational Studies
First developed in the 1980s at McMaster Medical School in Canada, the goal of
evidence based medicine seeks to improve the quality of clinical decisions by furnishing
health care providers with a framework to review and integrate published research into
their assessment and treatment of patient conditions (Sullivan, 2000). The term has since
been broadened to evidence based health care (EBHC) given its increasing scope of
practice. Large databases and health care providers ill-equipped to review enormous
volumes of information contributed to the need for EBM. To fully apply the principles of
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EBM, evidence based practitioners must have an understanding of the patient's
circumstances or predicament, to identify knowledge gaps and frame questions to fill
those gaps, to conduct an efficient literature search, to critically appraise the research
evidence, and to apply that evidence to patient care (Guyatt et al, 2000).
Randomized controlled studies provide the highest level of evidence, however the use
of observational studies is commonly required when comparing outcomes among health
care providers or institutions (Naylor & Guyatt, 1996). EBM provides guidelines to
determine validity when reviewing observational studies. The authors address the
importance of reporting on the quality and comprehensiveness of the secondary data
source. Of greatest importance is for patients to be similar in all ways except for the
outcome being measured, with the application of multivariate analysis to adjust for
differences (Naylor & Guyatt, 1996). In determining whether or not the data has been
adjusted for differences among patients, Naylor and Guyatt propose three core questions
in Table 2.1.
In addition to the above questions, the authors determine factors that may affect
outcomes by asking who, what, when, and where the service was provided. These key
questions were applied to the published research reviewed later in this chapter. The
sections below contain a review of the literature with application of EBM principles.

RESEARCH AND LITERATURE RELATED IN CONTENT
The purpose of this section was to review research and literature related in content. The
sections below discuss the methodology of health outcome measurement, cost issues
associated with those measurements, congestive heart failure (CHF) health outcomes
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Table 2.1: Evidenced Based Medicine:
Three Core Questions
1. Are the outcome measures accurate and
comprehensive?
2. Were there clearly identified, sensible
comparison groups?
3. Were the comparison groups similar with
respect to important determinants of
outcome, other than the one of interest?
Source: Naylor & Guyatt, 1996

specifically, and the economic burden of CHF on the health care industry including
methods to decrease costs.
Methodology of Health Outcome Measurement
Health outcome research findings guide the health care industry in the ultimate goal of
providing cost-effective, high quality of care. Schlenker (1996) proposed five convincing
reasons to analyze outcomes of care: (a) payers are demanding information about the
results of care delivery; (b) outcomes are an integral part of accreditation; (c) consumers
have a right to know about outcomes; (d) regulatory agencies demand information about
outcomes; and (e) outcomes represent the basic reason for providing care. Well-designed
methodologies of outcome measurement evaluation are essential due to the magnitude of
the decisions made based on outcome findings. Dobrzykowski (1997) recommends that a
comprehensive outcomes management system include patient-reported measures of
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health status and satisfaction, clinical measures of function and efficiency, and population
descriptive information including age, diagnoses, and comorbidity, in addition to
providing careful consideration for data collection protocol, training procedures, data
processing, and statistical analyses (Dobrzykowski, 1997).
A division of the Department of Health and Human Services, the Agency for Health
Care Research and Quality (formerly known as the Agency for Health Care Policy and
Research) is conducting numerous outcome measurement studies across the nation.
According to the AHRQ, outcome research has become the key to developing better ways
to monitor and improve the quality of care (AHRQ, 1999). The AHRQ seeks to provide
safe and effective outcome measurement data to develop guidelines for physicians to
follow, regardless of usual practices. The results of the agency's research are aiding in
the development of "report cards" that purchasers and consumers can use to assess the
quality of care in health plans.
Using an observational design, Jennings et al (1999) provided a valuable framework
for classifying outcome indicators by reviewing outcomes literature published since 1974
from medicine, nursing and health services outcome indicator research. By keyword
searching Medline, the Computerized Needs Oriented Quality Measurement Evaluation
System (CONQUEST), and the Healthcare Cost and Utilization Project (HCUP), the
authors compiled a list of indicators based on frequency of citation, differences in the
spectrum of philosophical perspectives, and empirical work examining actual outcomes
(Jennings et al, 1999). The authors recognized that the study was not comprehensive due
to the vast amount of published outcomes research since 1974 but did not state the actual
method of selecting the articles reviewed for the study. From their review they found a
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pattern that focused on three categories of outcomes research: patient-focused, providerfocused, and organization-focused. Although not identified in the review, they propose a
fourth category, population-focused outcomes, be added to the categories to provide
greater comprehensiveness. Table 2.2 further defines their findings and provides an
excellent tool for classifying outcome indicators. The authors conclude that the
integration of numerous outcome indicators from a variety of categories contributes to a
more balanced view of health care delivery as compared with focusing on a few common
indicators or only one category (Jennings et al, 1999).
Cost Issues Associated with Health Outcome Measurement
Cost issues associated with the results of health outcome measurements have produced
scrutiny among the patients, health care providers, and health insurance companies
regarding the objective to receive, provide, and reimburse cost-effective, high quality of
care. Health outcomes were found to be of great interest to managed care organizations
with multiple studies funded by HMOs. Managed care organizations (MCOs) use
outcome measurements to determine resource allocation and payment for various
illnesses.
Contracts between health care providers (HCPs) and HMOs are often based on
outcome measures. Given that HMOs focus on outcome measures to control their
expenditures for treatments, it has been discovered in this literature review that a
deficiency exists in research comparing health outcomes between FFS and HMO
insurance plans. Sullivan (1999) contends that although the need for more managed care
plan (MCP) and FFS plan comparison studies is obvious, the number of reliable studies
has been minimal.
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Table 2.2: Outcome Indicators According to Category
Subsets

Definition

Unit of
Measure

Unit of
Analysis

General
Examples

Sample
Indicators

Category: Patient-focused
DiagnosisFocused

Measures related to a
disease state or physical
condition; measured at
a discreet level providing
information about
changes in a patient’s
condition.

Patient

Patient or
subelements
within a
patient

Quantitative indices
(lab values, results of
tests of physiological
function), other
biomarkers, clinical signs
and symptoms

CBC
PO2
Apgar scores
Vital signs
Dyspnea
Weight gain

HolisticallyFocused

Measures related to a
person's responses or
adaptation to an alteration
in health; measured at a
global level to provide
objective and subjective
information about domains

Patient

Patient

Overall measures of
health status or healthrelated quality of life;
self-reports of knowledge
or satisfaction;
performance on
objective tests

Behavioral parameters
Comfort/discomfort
Functional status/physical
function
Psychological function
Social function
Activities of daily living
Mobility
Disability
Health status/health-related
quality of life
Patient knowledge
Patient satisfaction
Symptom management

Category: Provider-focused
Professional
Provider

Measures of provider
proficiency and use of
services

Patient

Provider

Complication rates;
interventions such as
appropriate use of
medications; provider
profiling

Appropriateness of
treatment
Sentinel events
Technical proficiency

Family
Caregiver

Measure of demands on
family members and
significant others
providing patient care

Caregiver

Caregiver

Measures of family or
caregiver burden

Caregiver burden/strain
Caregiver interaction

Category: Organization-focused
Measures aggregated
across patients to
provide evidence of
an organization’s
effectiveness

Patient

Organization

Measures across
organization's rates of
untoward events, e.g.
deaths, falls,
readmissions

Access to care
Cost
Length of stay
Morbidity
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Table 2.2: Outcome Indicators According to Category Continued
Mortality
Other rate-based outcomes
e.g., Caesarean sections,
infections, falls,
medication errors,
unplanned return to surgery
Source: Based on Jennings, B.M., Staggers, N. & Brosch, L. (1999). A classification scheme for outcome indicators.
Image: Journal of Nursing Scholarship, 31(4), 381-388.

He reports that only 2 comprehensive reviews of the literature published in peer-reviewed
journals have been performed since 1980, both by Miller and Luft (1994 and 1997).
Miller and Luft examined studies reporting on the differences in quality of care, cost, and
utilization rates between MCP and FFS plans and concluded that the quality of MCP care
was roughly the same as FFS care (Sullivan, 1999). Sullivan further reviewed their
findings for quality of care by controlling for breadth of insurance coverage, stating the
need to limit MCP and FFS plan comparisons to those studies in which coverage and
benefits in each setting are comparable due to differences in care seeking behavior based
on services covered. He found MCP care to be equal or inferior to the care provided by
FFS plans. Miller and Luft responded to Sullivan's review of their findings and purport
that by controlling for the above, the number of studies with results favorable to HMOs is
substantially reduced and the overall number of studies eligible for reanalysis would be
reduced to an insignificant amount. They state that adopting Sullivan's logic would be a
disservice to policy makers, consumers, and purchasers who need to better understand
potential consequences of differences in bundles of plan characteristics. In addition, they
state that improved measurement and reporting of both FFS and HMO plan performance
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would allow regulators to evaluate plans, and consumers and purchasers choose among
plans, on the basis of their comparative performance results (Miller, 2000).
In 1997, Margo Zink wrote of the ethical implications related to changes in the health
care industry brought about by managed care. Many divisions of health care services
have experienced increased financial burden due to reimbursement limitations set forth
by managed care organizations. Zink states that although ethical challenges are present,
managed care organizations experience greater responsibility and accountability due to
their focus on cost-effectiveness. MCOs maintain or attempt to maintain integrity by
basing reimbursement and approved procedures on health outcome measurements that
were previously determined. Douglas Olsen (1995) also wrote of the MCO ethical
implications in Ethical Cautions in the Use of Outcomes for Resource Allocation in the
Managed Care Environment of Mental Health. In addition to Zirk, Olsen postulated
ethical cautions for MCOs when basing reimbursement for mental health services on
outcome measurements. The author states there is difficulty in defining good outcomes
and recommends review based on process measurements instead of loosely defined
health outcomes.
Jones et al (1997) reported on the lack of nurse involvement in outcome measurement
initiatives in Policy Issues Associated with Analyzing Outcomes of Care. The authors
state that an endeavor on the local, national, and international levels has been undertaken
to provide adequate outcome measurement data and has neglected to include nurses as
valid resources in the research and development of such data. They go on to state that
nurses must get involved in the process and include their expertise in the development of
outcomes of care.
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In 1993, Alexis Wilson wrote of the need for patient outcomes in Bridging Cost and
Quality through Patient Outcome Measurement. According to the article, our health care
financing and delivery system contains more incentives to spend than to not spend
(Enthoven, 1991). In addition, our country is determined to receive top-notch
technological care, and if not received, litigation ensues. Due to high expectations, costs
soar. She concludes by stating that effective outcome measurements need to be instituted
at every level, and that they will become the tools used to evaluate and purchase health
care based on quality.
Congestive Heart Failure Outcome Measurement
Studies related to CHF health outcomes were also reviewed given the subject of this
study. A chronic debilitating illness, CHF afflicts an estimated 4.7 million Americans
with a 5-year mortality rate of 50% (Whellan et al, 1999). In a collaborative effort
between the American College of Cardiology, American Heart Association, and the
Agency for Health Care Policy and Research, a series of guidelines outlining
interventions for CHF were developed. Table 2.3 further defines those interventions.
Whellan et al (1999) suggest the guidelines need to add more recent clinical advances
such as initiation and titration of beta blockers, titration of ACE inhibitor to high target
dose, addition of spironolactone in patients with NYHA class III or IV, and maintenance
of digoxin concentration at lower end of therapeutic range (0.6 - 1.0ng/ml). They
conclude by recommending the best approach to CHF treatment include close follow up
and a multidisciplinary team comprised of a primary care physician, a cardiologist
specializing in heart failure, and other health care providers including nurses,
pharmacists, physical therapists, dieticians, and social workers.
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Table 2.3: CHF Treatment Recommendations
!

Asymptomatic patients with ejection fractions <35-40% should be treated with an
ACE inhibitor.

!

All patients with symptoms suggestive of heart failure should undergo an evaluation
including measurement of left ventricular function unless other disease is clearly
evident.

!

Presence or suspicion of heart failure and/or any of the following findings usually
indicates a need for hospitalization: evidence of acute myocardial infarction,
respiratory distress, pulmonary edema, severe complicating medical illness,
anasarca, symptomatic hypotension, heart failure refractory to outpatient
management.

!

Diuretics should be used for patients with heart failure and/or signs of significant
volume overload.

!

After a diagnosis of heart failure is established, all patients should receive
counseling on the disease, the prognosis, the symptoms to watch for, and the
different therapies available.

!

All patients with heart failure should be given a trial of ACE inhibitors unless
specific contraindications exist.

!

Patients with ischemic cardiomyopathy should be advised of the possibility of
revascularization unless they have a specific contraindication.

Source: AHCPR/Whellan et al, 1999

Smith & Konstam (1999) further support prevalence and cost by stating that CHF
remains the most common Medicare discharge diagnosis with overall direct costs in
excess of $10 billion in 1990, more than two thirds of the monies spent on hospital care.
Croft et al (1999) identified a national cohort of Medicare patients utilizing secondary
data obtained from Medicare hospital claims records (1984-1986) and Medicare
enrollment records (1986-1992) to observe 6-year heart failure survival in patients older
than 67 years of age. Probability of patient survival after their first hospitalization for
heart failure was determined utilizing Cox proportional hazards regression for groups
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defined by race, sex, age, Medicaid eligibility, and comorbid conditions. Utilized when
there are time-dependent censored observations, the Cox regression technique allows the
independent variables in the regression equation to vary with time, the dependent variable
being survival time of the patient (Dawson-Saunders & Trapp, 1994). The authors
recognize that the sample size of 170,239 patients 67 years or older admitted and
discharged with a primary diagnosis of heart failure in 1986 (total CHF claims submitted
in 1986 was 1.2 million) may negate the generalizability of their findings to the national
population, in addition to the fact that the study participants included only
noninstitutionalized subjects who were healthy enough to participate. Their study
revealed one third of the patients died within the first year and only 19% of black men,
16% of white men, 25% of black women, and 23% of white women survived 6 years
(Croft et al, 1999). In addition, an increase in mortality was associated with Medicaid
eligibility (white adults only) and diabetes. Their study further supports the needs for
prevention and proper disease management of this chronic debilitating illness.
In a well-designed single center prospective randomized trial study, Rich et al (1995)
assessed the effects of multidisciplinary interventions on rate of readmission, quality of
life, and the overall cost of medical care for high risk, hospitalized CHF patients 70 years
or older. Study participants were randomized with the use of a treatment and control
group. Results revealed 90 day survival rates without readmission to be 75 patients in the
control group (53.6%) compared to 91 patients in the treatment group (64.1%) with no
significant difference noted. However, a significant difference was determined when
analysis was limited to survivors of the initial hospitalization (54.3% in control group and
66.9% in the treatment group, p=0.04). The authors concluded that a multidisciplinary
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treatment strategy could reduce hospital readmissions for elderly CHF patients (Rich et
al, 1995).
Economic Burden of CHF on the Health Care Industry
As discussed earlier in the chapter, the economic burden of CHF on the health care
industry is overwhelming. The section below provides further analysis of those studies
examining the economic burden of CHF.
Xuan et al (2000) performed a retrospective review of medical and pharmacy claims
to examine the costs and treatment patterns for CHF patients in a managed care
population. Patients with a diagnosis of CHF and claims eligibility of at least one year
were selected from 6 independent-practice-association HMO enrollee lists for the
calendar year 1994. They examined charges incurred by CHF patients for the 6 months
following the initial CHF medical claim and the treatment received by those patients.
The study revealed 378 of the 2777 CHF patients (14%) were admitted to the hospital
with a cost of almost $3 million. In addition, 78% of the population received prescription
drugs, an average cost of $942 per patient (Xuan et al, 2000). ACE inhibitors were the
most commonly prescribed drug. Fifty-four percent of the total CHF treatment costs
went to hospitalization, and prescription drugs accounted for 38% of costs. The authors
conclude that decreasing hospital admissions/readmissions could markedly reduce the
economic burden of CHF on the managed care population and suggest further research to
conclude whether or not increased use of prescription drugs could contribute to decreased
hospitalization rates and overall costs (Xuan et al, 2000).
Rauh et al (2000) performed a non-randomized controlled trial to observe the effects
of a multidisciplinary treatment approach on length of stay, admission and readmission
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rates, and costs to both patient and provider. Participants were selected based on
presence of a CHF diagnosis with 407 patients in control group and 347 in treatment
group. Via telephone interviews during the 90 days following discharge, the treatment
group received intensive patient and family education on diet, compliance, and symptom
recognition, in addition to outpatient infusion of inotropic agents and aggressive
pharmacologic treatment for patients with advanced CHF (Rauh et al, 2000). The authors
did not provide information on refusals, exclusion of patients, or whether patients were
lost to follow up. Their results revealed the mean length of stay for the treatment group
was 1.6 days less than the control group (statistically significant at .05 risk level) with
decreased costs associated with decreased length of stay. The authors conclude that a
multidisciplinary CHF program can improve patient care in the hospital setting while
significantly reducing costs to both patients and institutions (Rauh et al, 2000).
In conclusion, the overwhelming majority of studies support the need for more efforts
aimed at prevention and control of exacerbation of CHF to improve outcome
measurements and decrease overall costs. In addition, further studies revealing CHF
health outcome variations between FFS and HMO insurance plans are needed to
determine whether a particular plan provides greater or lesser care in the presence of
controlled expenditures.

RESEARCH AND LITERATURE RELATED IN METHODOLOGY
The purpose of this section was to review research and literature related in
methodology. The previous section explored the various elements of health outcome
measurement and CHF treatment costs, whereas the methodology section explores the
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value of secondary data in well-designed research both related and unrelated to health
outcome measurement.
The methods applicable to collecting health outcome data include primary data
obtained from surveys or instruments prepared by the researcher. More easily procured,
secondary data obtained from hospital, federal, or other administrative databases provides
an excellent source of valid research data. The assessment tool currently under study and
being considered for dissertation use involves an instrument developed by a board of
cardiologists and other cardiac practitioners at the University of Tennessee Medical
Center, Knoxville (UTMCK) that measures various CHF outcomes on selected patients at
time of discharge. The instrument was developed, in part, due to a nationwide study that
CMS is conducting utilizing a federal Quality Management Review form that
participating hospitals complete upon discharge. The form was created by CMS who is
analyzing the data for specified quality of care indicators. The UTMCK is participating
in CMS's study on measuring health outcomes related to one of the six possible areas of
participation, CHF. UTMCK developed a comprehensive instrument that collected more
extensive CHF data than the form provided by CMS. CMS's form clearly delineates and
measures the quality of care administered to the patient in the hospital and upon
discharge, based on pre-defined criteria that has been deemed safe and effective treatment
for CHF patients. The form does not allow for patient satisfaction parameters in defining
quality of care, rather bases the quality on medical treatment. In addition to the quality of
care provided the type of insurance is also documented, thus enabling the researcher to
obtain health outcome data and compare it by insurance plan. No studies using this form
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have been found in the literature review. Further explanation of the UTMCK instrument
from which this study collected secondary data is discussed in chapter three.
Hanchak & Kelly (1997) described the benefits of secondary data analysis to evaluate
health outcomes in Using Administrative Data to Evaluate the Quality of Care. The
advent and advancement of medical informatics has opened a technological frontier for
data collection and evaluation. The authors describe how U.S. Quality Algorithms, Inc.
(USQA) uses administrative data to measure and improve the quality of medical care in
the United States. The Health Profile Database, which can be accessed to collect and
measure quality of medical care, includes information regarding services provided by
primary care physicians, specialists, and hospitals that are paid through capitation or feefor-service reimbursement models. In addition, information regarding pharmacy usage,
laboratory and test results, patient satisfaction, and health status information can be
retrieved as well. The Health Profile Database focuses on chronic medical conditions,
utilizing ICD-9, CPT-4, pharmacy codes, laboratory test results, and patient demographic
information to classify patients within the database. The authors conclude by stating that
costly treatments invoked by chronic diseases can be managed more effectively by
defining the conditions that will benefit from further medical treatment. The following
studies utilize secondary data in their methodology.
In Correlates of Health Status among Black and White Elderly, Yu et al (1998)
performed a study utilizing secondary data from the National Health Interview Survey
(NHIS) to examine the health status of non-institutionalized elderly in the United States.
The NHIS is a health interview survey distributed annually by the National Center for
Health Statistics. The current study collected information regarding health and other
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characteristics of each household member. The computer program SUDAAN was used
to analyze the findings, which allows incorporation of the complex sampling design of
the NHIS into the variance estimation and the odds ratios (Yu et al, 1998). The
respondents were grouped into young-old (65-79) and old (80 years and older) groups.
The elderly were asked by the NHIS to respond to self assessed health status questions
with possible responses including excellent, very good, good, fair or poor. Black and
white populations were analyzed separately with other racial groups excluded from the
study. Logistic regression was used to examine correlates of health status. Excellent and
very good responses were grouped together as excellent health and good health was
deemed the reference category. Comparisons were made between excellent vs. good
health and poor vs. good health. Results revealed 30% of elderly reported excellent or
very good health and 14% reported poor health. Of the young-old and old categories,
Whites reported better health than Blacks in both categories. Of the White young-old
who reported excellent health, they tended to be single, never married, better educated,
and/or with higher income, fewer activity limitations, fewer chronic illnesses, and fewer
physician visits in the last 12 months than the White old or either Black groups. Higher
educational levels reflected higher health reporting. Further analysis regarding self
assessment of health status by ethic group is needed to explain whether or not variation in
self reporting is due to actual or perceived illness or disability.
Utilizing both primary and secondary data obtained from a federal database, Carroll et
al (1999) explored parental concern over teens contracting AIDS. Utilizing the Health
Belief Model and a family systems perspective as a framework, they first collected
secondary data from the National Commission on Children: 1990 Survey of Parents and
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Children, and then collected primary data from telephone interviews. The purpose of the
study was to determine what factors predicted an adolescent's worry about contracting
AIDS and to what extent parents agreed with their children. Participants for this study
were selected based on those who responded yes to "worry about AIDS" in the national
study, and were further sub-sampled utilizing a random sample from telephone numbers
as well as supplemental random samples of African American and Hispanic children.
The data was collected over the telephone with interviews lasting approximately 30
minutes. Children ages 14 to 17 years of age were asked, "How much do you worry that
you will get AIDS someday" and parents were asked, "How much do you worry that
he/she will get AIDS?" Responses with missing data or "don't know" responses were
excluded from the study. Data analysis was performed using Pearson's chi-square to
compare the teen's worry score with influencing factors. Cramer's Vor Kendall's Tau was
used to test the strength of the relationships (Carroll et al, 1999). Results revealed 46%
of the parent/teen pairs agreed in their responses about worry over contracting AIDS.
In summary of other studies utilizing nonfederal databases to collect secondary data,
several studies were performed to measure the impact of managed care on health care
utilization and patient outcomes following emergency department visits. The method
included collection of secondary data from the patient's medical record. O'Neil et al
(1994), found that HMO enrollees were less likely to be hospitalized, less likely to utilize
emergency department services, and have fewer visits to a primary provider in the 4
month follow-up period. The researchers controlled for health status at baseline and
found no differences at the end of the 4-month period. Pearson (1994) reported on the
findings of a study performed to measure the impact of membership in an HMO on
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hospital admission rates for patients presenting to the emergency department with acute
chest pain. Analysis of insurance status along with patient outcome data was performed
after grouping patients in low, medium, and high-risk cohorts. The patient's medical
record was used to collect the secondary data. The researchers found that hospital
admission rates were similar for all high-risk patients, regardless of payment source.
Surprisingly, HMO admission rates for low and medium risk patients was higher than for
commercial insurance or other payment source. The findings are contrary to previous
studies, which report decreased hospitalization in HMO enrollees.
Concluding the methodology review, it is apparent that federal databases and medical
records are an excellent source of secondary data. Select federal databases are accessible
through the Internet at the Center for Disease Control and Prevention's web site
(www.cdc.gov). In addition to the above, the CDC publishes reports through the
National Center for Health Statistics, providing even greater access to volumes of
national data. Given the accessibility of information available through federal databases,
they provide an excellent source for studies concentrating on secondary data analysis.

RESEARCH AND LITERATURE RELATED IN CONTENT AND
METHODOLOGY
The purpose of this section was to review research and literature related in content and
methodology. This section reviews general studies utilizing secondary data to compare
health outcomes by insurance type, including studies related specifically to CHF. Studies
utilizing secondary data to compare health outcomes by insurance type are reviewed
below.
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Studies Utilizing Secondary Data to Compare Health Outcomes by Insurance Type
Utilizing CMS cost reports, Cher & Lenert (1997) reported on the possibility of
potentially ineffective care (PIC) provided to Medicare patients enrolled in HMOs and
traditional fee-for-service health plans based on outcome data for patients in critical care
units. The method included analysis of secondary data obtained from a Medicare
administrative database for the state of California. The database used, The Medicare
Provider Analysis and Review (MEDPAR), contained information on age, sex, race, total
hospital charges, length of hospital stay, ICU care indicators, International Classification
of Diseases (9th Revision), Clinical Modification diagnosis and procedure codes, length
of time from hospital admission to death during approximately 1 year of follow-up, and
CMS indicators for reimbursement method (HMO vs. other). In addition to the
MEDPAR database, CMS's cost report minimum data set for each hospital was included.
The data includes indicators such as type of hospital (rural vs. non-rural, teaching vs.
non-teaching), hospital and ICU size, total hospital operating costs and charges, number
of full-time residency positions, bed availability, and bed use (Cher & Lenert, 1997). In
addition to the above, 1994 wages for the metropolitan statistical areas of California
obtained from CMS's website was included in the data. All patients who received critical
care services in the state of California in the fiscal year 1994 were included in the study.
The relationship between risk of a PIC outcome and HMO membership was determined
after adjusting for severity of illness and differences in organizational features of the
treating institution (Cher & Lenert, 1997). They found that PIC was less common among
HMO enrollees, however HMO enrollees were less likely to die in the hospital (possibly
indicating a decreased hospitalization rate for HMO enrollees). If HMO enrollee
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hospitalization rates are lower, PIC results may be skewed due to lack of data on those
enrollees who die outside of the hospital. The authors concluded that HMO plans may
avoid misuse of critical care resources near the end of life compared to FFS plans.
Other related studies included Riley et al (1999) who reported their findings in the
Journal of the American Medical Association, Stage at Diagnosis and Treatment Patterns
among Older Women with Breast Cancer: An HMO and Fee-For-Service Comparison.
Utilizing cancer registry data from the National Cancer Institute's Surveillance,
Epidemiology, and End Results (SEER) program (data linked to Medicare enrollment
records), the researchers investigated the treatment patterns for elderly women with
breast cancer based on stage at diagnosis and type of insurance. HMO and fee-forservice (FFS) insurance plans were compared. The SEER database includes information
on month and year of diagnosis, cancer site, patient demographics, extent of disease at
diagnosis, and therapy administered within 4 months of diagnosis (Riley et al, 1999).
Women 65 or older who were entitled to Medicare part A and B benefits with breast
cancer between 1988 and 1993 were included in the study. Medicare enrollment records
disclosed information regarding enrollment in either HMO or FFS setting. Cases with
bilateral disease, those with no mass found, those who switched from HMO to FFS or
vice versa within 4 months of diagnosis, and cases not treated by either breast conserving
surgery or total/modified radical mastectomy were excluded from the study. Information
regarding stage at diagnosis and treatment patterns was gleaned from the SEER database
and then compared based on HMO or FFS enrollment. Results revealed HMO enrollees
were less likely to have breast cancer diagnosed at late stages than FFS patients. In
addition, women diagnosed with early stage breast cancer received similar rates of breast
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cancer surgery regardless of payment source. For those undergoing surgery, HMO
enrollees were more likely to receive radiation therapy. In conclusion, the authors state
that the differences reported were often inconsistent and that HMO enrollees did not
appear to have access problems (HMO agreeing to pay for the treatment) obtaining
radiation therapy after breast cancer surgery than women in FFS settings.
Laurance Baker (1999) studied the variations in treatment levels for fee-for-service
Medicare patients based on the prevalence of managed care in geographically defined
areas. In Association of Managed Care Market Share and Health Expenditures for FeeFor-Service Medicare Patients, Baker used secondary data from a CMS database to
compare expenditures for the care of Medicare fee-for-service beneficiaries in areas with
and without a high HMO market share. The method included comparing Medicare
market share between predominantly HMO and FFS areas. The main independent
variable was the system-wide HMO market share in each market area (Baker, 1999).
Due to the possible nonlinear relationship between HMO market share and expenditures
(presence of a greater number of healthier members transferred to HMO plans with
sicker, more costly patients left in FFS plans) the expenditures would rise per capita in
FFS plans as the HMO enrollment increased, therefore inclusion of both system wide
HMO market share and its square was performed. The findings reported that in all areas
defined, an increase in HMO market share reflected a decline in Medicare fee-for-service
expenditures. A direct association between high levels of managed care and decreased
fee-for-service Medicare expenditures was determined. The above study further supports
the applicability of secondary data previously obtained by the Centers for Medicare and
Medicaid Services to studies relevant to the data on hand.
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Himmelstein et al (1999) compared 14 quality of care measures for investor-owned
and not-for-profit HMOs. Using data obtained from the National Committee for Quality
Assurance's Quality Compass 1997, including the Health Plan Employer Data and
Information Set (HEDIS) and HMO accreditation surveys, the researchers found that
investor-owned plans scored lower on all 14 quality of care indicators that were assessed.
After controlling for model type, geographic region, and the method each HMO used to
collect data, the researchers determined investor-owned plans consistently scored lower
in all areas reviewed. The group concluded that based on their research findings,
investor-owned HMOs deliver a lower quality of care than not-for profit HMOs.
Sidorov et al (1997) conducted a descriptive study to measure the success of a tobacco
cessation program that compared quit rates among managed care enrollees and (not
stated) non-managed care plans. They found that non-HMO enrollees were less likely
than HMO enrollees to achieve success. They concluded by stating that tobacco
cessation programs were more likely to benefit HMO enrollees, although the benefit to
non-HMO members was significant. The funding source for the study could not be
determined.
Yelin, Criswell, & Feigenbaum (1996) reported health outcome differences among
rheumatoid arthritis (RA) patients in prepaid group practice/HMO (PGP) and fee-forservice (FFS) settings in Health Care Utilization and Outcomes Among Persons with
Rheumatoid Arthritis in Fee-For-Service and Prepaid Group Practice Settings. Utilizing
annual telephone interviews for follow-up on an 11-year study, the authors concluded
that despite literature findings prior to onset of the study, they found no difference in the
quality or quantity of care provided to RA patients in either the PGP or FFS setting.
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Given their findings, the authors conclude that method of reimbursement, specifically
PGP or FFS, does not affect the quality of health care received.
CHF Studies Comparing Outcomes by Insurance Type
A significant deficiency in literature existed at the time of this literature review that
compared CHF health outcomes between FFS and HMO insurance plans. The following
studies utilized secondary data to compare CHF outcomes by insurance type.
Hanyu et al (1998) examined CHF outcomes by insurance type in Managed Care and
Outcomes of Hospitalization among Elderly Patients with Congestive Heart Failure.
With the objective of examining the effects of HMO enrollment on the outcomes of
hospitalization, the authors conducted a retrospective cohort study that reviewed the
Oregon hospital discharge data set for patients 65 years or older with a diagnosis of CHF
in the year 1995. CHF patients were divided into 6 insurance groups that included
managed care, Medicare, Medicaid, commercial or private insurance, self-pay, and other
(not defined). Data reviewed from the hospital discharge data set included admission to
hospital via emergency department, length of hospital stay, in-hospital mortality rate, and
readmission rate. The study found that managed care patients were more likely to be
admitted to the hospital via the emergency department. After adjusting for age, sex, and
comorbidity, managed care length of stay was similar to that of commercial or private
insurance patients, but experienced a shorter length of stay compared to Medicare, selfpay, and other patients. No comment was made on differences between managed care
and Medicaid patients. No difference in the in-hospital mortality rate was found between
the insurance groups. Readmission rates were higher in managed care patients than for
commercial insurance or Medicare patients, but after adjusting for confounding variables
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no significant differences were found. The authors conclude that no association between
managed care and poor short-term outcomes of hospitalization in CHF patients exist but
state that further attention needs to be paid to the increased use of emergency departments
by managed care patients (Hanyu et al, 1998).
Philbin & DiSalvo (1998) examined the influence of payer status on the process of
care and resource utilization among patients hospitalized for CHF in Managed Care for
Congestive Heart Failure: Influence of Payer Status on Process of Care, Resource
Utilization, and Short-term Outcomes. In a retrospective study utilizing secondary data
obtained from the Statewide Planning and Research Cooperative System database, they
reviewed information on patients discharged in 1995 from New York State hospitals.
Patients were separated by insurance plans that included HMO, indemnity, Medicaid feefor-service, and Medicare fee-for-service. Information collected included demographics,
comorbid illness, process of care, length of stay, hospital charges, mortality rate, and
CHF readmission rate. They found that noninvasive procedures were used with similar
frequency and invasive procedures were used greater in HMO and indemnity insurance
patients. After adjusting for patient characteristics and hospital type and location, HMO
patients had shorter length of stay and lower hospital charges, in part due to decreased
length of stay (Philbin & DiSalvo, 1998). The authors conclude that managed care plans
provide similar access to clinical services with fewer charges but further prospective
study of short-term outcomes is needed to determine if the difference is due to patient
mix or quality of care.
In conclusion, lower costs are associated with managed care plans, however the
studies agree that further research is needed to determine whether or not it is due to fewer
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procedures and/or shorter hospital stays, or due to better case management by the
managed care organization.
Concluding the content and methodology review, secondary data can be useful to
subsequent studies. Administrative data available through previous studies conducted by
hospitals, CMS and other administrative sources can be gleaned for additional valuable
information. Unfortunately, the instrument to be used in the research at hand has no prior
studies reported, although the information will be made available to researchers in the
future.

SUMMARY
In conclusion, the literature review revealed a deficiency of studies devoted to
measuring health outcomes based on insurance type. Given that managed care has
continued to grow and is unlikely to decline in fiscal appeal, objective measurement of
health outcomes for MCO enrollees, HMO in particular, is crucial for the development of
safe, effective health plans that provide adequate health care. Without accountability to
documented objective outcome data, managed care organizations may provide their
enrollees with decreased quality of care in their pursuit of financial gain. As the literature
review reveals, further studies comparing outcome data between managed care plans and
fee-for-service plans are critical to the future of accountable health care service financing.
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CHAPTER THREE
METHODS AND PROCEDURES
INTRODUCTION
The purpose of this chapter was to define the study population, the instrument to be
used for data collection, and the procedures for treating the data. The population
included patients treated for and diagnosed with congestive heart failure at an East
Tennessee hospital. The method for data collection included retrieval of secondary data
from a CHF monitor developed by the hospital to investigate variables specific to CHF
health outcomes. The sections below describe the population, instrument, and research
design in further detail.

STUDY POPULATION
The purpose of this section was to describe in detail the population to be studied as
well as the geographical area from which the sample was selected. The sample included
patients discharged from the University of Tennessee Medical Center in Knoxville,
Tennessee (UTMCK) with a diagnosis of congestive heart failure who were enrolled in
either a fee-for-service or health maintenance organization health insurance plan. The
attending physician and/or cardiologist determined the diagnosis of congestive heart
failure. Eligible patients included those in which UTMCK's CHF monitor had been
administered and was limited to enrollees of FFS or HMO insurance plans. The
following section describes pertinent statistical data regarding the population studied.
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Population Statistics
The total population for East Tennessee in 1998 was 633,183, compared to
366,846 in Knox County and 5,430,621 statewide**. The 1998 population by gender
included 329,205 females and 303,978 males in East Tennessee, 192,922 females and
173,924 males in Knox County, and 2,830,813 females and 2,599,808 males statewide.
Of significance to the need for this study, the leading cause of death in 1997 for the state
of Tennessee was cardiovascular diseases. The 1997 death rate per 100,000 for diseases
of the heart in Knox County Tennessee was 265.8, compared to 312.1 in East Tennessee
and 308.1 statewide (no Tennessee data specific to congestive heart failure was
available). The 1997 diseases of the heart death rates per 100,000 by gender included
298.1 females and 327.3 males in East Tennessee, 259.2 females and 273.2 males in
Knox County, and 297.6 females and 319.5 males statewide. The study population
included a convenience sample of both males and females consisting of all patients
admitted to UTMCK with a primary diagnosis of CHF and discharged with the same
primary diagnosis during the study period. Given the significant prevalence of the
disease in both genders (although higher in males), the study included both genders but
did not separate by race or ethnicity.
The East Tennessee environment is rich in vegetation and forestry, but unfortunately the
culture of the area patronizes a lifestyle consistent with increased cardiovascular disease
risk. Risk factors such as high fat foods including meats and vegetables fried in oil,
*

Nonmetropolitan East Tennessee region includes Anderson, Blount, Campbell, Claiborne, Cocke,
Grainger, Hamblen, Jefferson, Loudon, Monroe, Morgan, Roane, Scott, Sevier, and Union counties.

*

All statistics obtained from the Tennessee Department of Health and Health Information Tennessee web
site
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smoking, and obesity are all prevalent in East Tennessee. More studies addressing the
outcomes of diseases brought about by poor lifestyle practices are needed. The
quantification of congestive heart failure health outcomes by insurance plan can
contribute to increased community awareness, as well as providing accountability to
insurance companies for treatments provided or withheld.

INSTRUMENTATION
The purpose of this section was to describe in detail the instrument and methods used
to obtain the data. The following sections detail the instrument selected and the method
of administration, including the follow-up procedure for insufficient sample size and data
tabulation.
Selection of the Instrument
For the purpose of this study, secondary data were collected from UTMCK's CHF
monitor (see Appendix A). After collaborating with CMS to collect CHF outcome data
for a national study, UTMCK developed their own CHF instrument utilizing a panel of
physicians that included cardiologists to modify and expand the original CMS instrument
in order to collect more comprehensive CHF data not available on the CMS instrument.
Validity and reliability of the instrument remains an assumption given that it was not
tested for validity and reliability after modification.
The health outcome measurements for this study obtained from UTMCK's CHF
monitor included the following:
1.

Length of stay (days)

2.

Mortality
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3.

Gender (male/female)

4.

Payor (FFS/HMO)

5.

Readmitted within 30 days of discharge with related condition

6.

Attending physician (cardiology, medicine, family practice, other)

7.

Treated with ACE inhibitor

8.

Follow-up with a health care provider within 2 weeks scheduled at
discharge

9.

Documentation of instruction (discharge instructions)
A.

Diet

B.

Weight

C.

Medications

D.

Activity level

E.

CHF teaching booklet

In addition to the above health outcome measurements, the type of insurance was
recorded with selection limited to patients enrolled in either a fee-for-service or health
maintenance organization insurance plan.

METHOD OF ADMINISTRATION
Utilizing registered nurses in the Department of Medical Management, UTMCK
originally collected outcome data via chart reviews. Secondary data analysis of the CHF
monitor for this study was performed by registered nurses with sample selection based on
a diagnosis of CHF and enrollment in a FFS or HMO insurance plan. The health
outcome information collected was described in the previous section.
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FOLLOW-UP PROCEDURE FOR INSUFFICIENT SAMPLE SIZE
In the event a sample size less than 150 is obtained from the available secondary data
sample, the sample size can be increased by performing further chart reviews to provide
more primary data. The addition of primary data from the same instrument is feasible
given that access to the University of Tennessee Medical Center's CHF patient population
has already been approved. Approval from the hospital Institutional Review Board
would be obtained prior to accessing the medical record for more primary data.

DATA TABULATION
Once the CHF outcome measurements were collected through secondary data analysis
of the CHF monitor, they were compared by insurance plan. All of the afore described
indicators will be compared by insurance plan. The section below defines how the data
was analyzed.

PROCEDURES FOR TREATING THE DATA
The purpose of this section was to describe the procedures for treating the data. Once
the data was obtained, the following statistical methods were applied to the data.
An exposed odds ratio was utilized to determine an estimate of relative risk, or the
relationship between two characteristics (insurance plan and outcome). The test
determines the odds in favor of being exposed for diseased subjects divided by the odds
in favor of being exposed for non-diseased subjects. The test can also be used to measure
association between exposure and disease. For this study, multiple 2 x 2 contingency
tables were developed where insurance type equaled exposure (e.g. FFS insurance, yes or
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no) and outcome equaled each selected variable from the CHF instrument (e.g. treated
with ACE inhibitor, yes or no). Utilizing SPSS for statistical analysis, tables were
created from collected data that calculated odds ratios (risk estimates) between selected
variables. Table 3.1 provides an example of one contingency table that presented the
outcome as "treated with ACE inhibitor" and the exposure as "fee for service insurance."
The two possible exposures were 1) enrollment in a FFS insurance plan and 2)
enrollment in an HMO insurance plan. The following odds ratio outcomes were collected
for FFS insurance type and then again for HMO insurance type:
1. Mortality
2. Readmitted within 30 days of discharge with related condition
3. Treated with ACE inhibitor
4. Follow-up with a health care provider within 2 weeks scheduled at discharge
5. Documentation of teaching (discharge instructions)
A. Diet
B. Weight
C. Medications
D. Activity level
E. CHF teaching booklet
For each of the above outcomes, a 2 x 2 contingency table was created for members of
FFS insurance plans and again for members of HMO insurance plans. SPSS software
provided statistical analysis and calculated the risk estimates at a 95% confidence interval
for each of the above exposure and outcome combinations.
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Table 3.1: Odds Ratio Example

Outcome

Exposure

Fee-forService
Insurance

Treated with ACE Inhibitor
Yes
No
Total
x
x
x
Yes
No

x

x

x

Total

x

x

x

In addition to these outcome measures, an independent sample t-test was used to test
the null hypothesis that average length of stay of HMO members is equal to the average
length of stay of FFS members. To determine whether or not the class of attending
physician is dependent upon the type of insurance, a Pearson's chi-square test of
independence was used. Table 3.2 summarizes each outcome measure collected and the
statistical test used to analyze the data.

SUMMARY
In conclusion, instrument selection was followed by the development of a
methodology most appropriate for the type of data to be collected in this case-control
study. Composed of multiple risk estimates, the exposed odds ratio is an appropriate test
to determine whether a significant difference in the selected variables exists. In addition
to the exposed odds ratio, tests such as the independent sample t-test and Pearson's chisquare test of independence can efficiently analyze data when testing the null hypothesis.
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Table 3.2: Data Analysis Summary
Outcome Measure

Statistical Test

Average length of stay (days)

Independent sample t-test to test the
null hypothesis that average length
of stay of FFS members is equal to
the average length of stay of HMO
members.

Mortality (yes or no)

Exposed
odds ratio

Gender (male or female)

Categorical
definition

Payor (FFS or HMO)

Categorical
definition

Readmitted w/in 30 days of discharge
with related condition (yes or no)

Exposed
odds ratio

Attending physician (cardiology,
medicine, family practice, or other)

Pearson's chi-square test of
independence

Treated with ACE inhibitor (yes or no)

Exposed
odds ratio

Follow-up with health care provider
scheduled at discharge (yes or no)

Exposed
odds ratio

Documentation of discharge teaching
(yes or no)

Exposed
odds ratio
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The following chapter provides the detailed results of data collection utilizing the above
methodology.
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CHAPTER IV
ANALYSIS AND INTERPRETATION OF DATA
INTRODUCTION
The purpose of this chapter was to present analysis of the data. The chapter was
divided into the following sections: 1) subject data, 2) results of the study, 3) analysis of
the research questions 4) interpretation of the data and 5) summary.

SUBJECT DATA
The sample included 154 subjects discharged from the University of Tennessee
Medical Center, Knoxville (UTMCK) with a primary diagnosis of CHF between the
years 1996 to 2000. A stratified random sample of subjects was selected based on a list
of all attending physicians at UTMCK caring for patients discharged with a primary
diagnosis of CHF during the years specified above. According to type of insurance, only
those patients with FFS or HMO insurance plans were selected. The age range was 19 to
98, consisting of 82 females and 72 males. The data revealed a disparity in age groups
between insurance plans, with FFS plans comprising a larger percentage of subjects ages
67 and up. Table 4.1 summarizes the distribution by age and insurance plan with
comprehensive data on age distribution by insurance plan presented in Appendix B.

RESULTS OF THE STUDY
The following section describes in detail the results of the statistical tests defined in
the Data Analysis Summary displayed in Table 3.2. An alpha of .05 was selected for
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level of significance criterion.
To test the null hypothesis that average length of stay (LOS) of FFS members is equal
to the average LOS of HMO members an independent sample t-test was performed. The
mean LOS was 5.32 and 4.95 days for FFS and HMO members respectively. After
confirming homogeneity of variances, the t-test revealed no significant difference in LOS
between the insurance plans. Calculation of design power revealed a power of 7% with a
difference of 2.5 days needed to obtain a power of 80%. Table 4.2 reveals less than half
of a day difference in length of stay between the insurance plans. Table 4.3 displays the
results of the t-test.
To determine relative risk of mortality by insurance plan, an exposed odds ratio test
was performed. Out of the 154 subjects, all 6 cases of mortality were found in FFS
insurance plans, ages 67 and up. Although all 6 cases of mortality were found in FFS
insurance plans, the statistical test revealed no increased risk of mortality by insurance
plan. The results of the odds ratio are displayed in Table 4.4 with the distribution of
mortality cases by insurance plan presented in Table 4.5.

Table 4.1: Age Distribution by Insurance Plan
Payor
FFS
Age Category 66 or less

Count
% within Age Category

67+

Count
% within Age Category

Total

Count
% within Age Category

HMO

Total

22

36

58

37.9%

62.1%

100.0%

93

3

96

96.9%

3.1%

100.0%

115

39

154

74.7%

25.3%

100.0%
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Table 4.2: Mean Length of Stay by Insurance Plan
Payor
LOS

N

FFS
HMO

Mean

Std. Deviation

Std. Error Mean

115

5.32

4.173

.389

39

4.95

6.304

1.009

Table 4.3: Independent Samples T-Test
LOS
Equal variances
Equal variances not
assumed
assumed
Levene’s Test for
Equality of Variance

F

1.341

Sig.

.249

t

.420

.345

df

152

49.768

Sig. (2-tailed)
Mean
difference
Std. Error
Difference

.675
.37

.732
.37

.889

1.082

Lower
Upper

-1.382
2.129

-1.800
2.546

T-Test for Equality of
Means

95% Confidence
Interval of the
Difference

Table 4.4: Risk Estimate of Mortality by Insurance Plan
Value
For cohort Mortality = No

.948

N of Valid Cases

154

95% Confidence Interval
Upper
Lower
.908

.989
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Table 4.5: Mortality Distribution by Age and Insurance Plan
Payor
Age Category
66 or less

FFS
Mortality

No

Count
% within Mortality

Total

Count
% within Mortality

67+

Mortality

Yes

Count
% within Mortality

No

Count
% within Mortality

Total

Count
% within Mortality

HMO

Total

22

36

58

37.9%

62.1%

100.0%

22

36

58

37.9%

62.1%

100.0%

6

6

100.0%

100.0%

87

3

90

96.7%

3.3%

100.0%

93

3

96

96.9%

3.1%

100.0%

To control for age, Table 4.6 further defines relative risk of mortality by displaying
results by age groups 66 or less and 67+.
To determine risk of hospital readmission within 30 days of discharge with a related
diagnosis by insurance plan, an exposed odds ratio test was performed. The data revealed
22.6% of FFS cases and 25.6% of HMO cases were readmitted to the hospital within 30
days of discharge with a related diagnosis. The distribution of readmission cases by
insurance plan is displayed in Table 4.7. A risk estimate determined no increased risk of
readmission between insurance plans as displayed in Table 4.8.
A Pearson's chi-square test of independence was performed to determine if the type of
attending physician was dependent upon insurance plan. The data revealed 43.5% of
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Table 4.6: Risk Estimate of Mortality by Age and Insurance Plan
95% Confidence Interval
Age Category

Value

66 or less

Odds Ratio for
Mortality (No / .)

67+

For cohort Payor = FFS

Lower
.

a

1.034

N of Valid Cases

Upper

.996

1.075

96

a. No statistics are computed because Mortality is a constant.

Table 4.7: Distribution of Readmission Cases by Insurance Plan
Readmitted within 30 days
with CHF related diagnosis?
Yes
No
Payor

Total

FFS
HMO

26
10

89
29

115
39

Total

36

118

154

Table 4.8: Risk Estimate of Readmission Cases by Insurance Plan
Value
Odds Ratio for Payor
(FFS/HMO)
For cohort readmitted
within 30 days with CHF
related diagnosis? = Yes
For cohort readmitted
within 30 days with CHF
related diagnosis? = No
N of Valid Cases

95% Confidence Interval
Lower
Upper

.847

.365

1.965

.882

.468

1.660

1.041

.844

1.283

154
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FFS cases and 46.2% of HMO cases received primary attending services from a
cardiologist. The distribution of subjects by attending physician (cardiology, family
practice, medicine, or other) and insurance plan is displayed in Table 4.9. Results of the
Pearson’s chi-square test of independence revealed no significant association between
attending physician and insurance plan. Table 4.10 further defines the results.
To determine risk of being treated with an ACE inhibitor by insurance plan, an
exposed odds ratio was performed. The data revealed 64.3% of FFS cases and 71.8% of
HMO cases were prescribed an ACE inhibitor. The distribution of subjects prescribed an
ACE inhibitor by insurance plan is displayed in Table 4.11. Results of the odds ratio
revealed no increased risk of being prescribed an ACE inhibitor between the insurance
plans. Table 4.12 below displays the results of the test.
To determine if follow-up with health care provider scheduled at discharge was
affected by insurance plan, an exposed odds ratio test was performed. The data revealed
87% of FFS cases and 92.3% of HMO cases were scheduled for follow-up within 2
weeks following discharge from the hospital. The distribution is displayed in Table 4.13.

Table 4.9: Distribution of Subjects by Attending Physician and Insurance Plan
Cardiology
Payor

Attending Physician
Family Practice Medicine

Other

Total

FFS
HMO

50
18

16
5

43
13

6
3

115
39

Total

68

21

56

9

154

52
Table 4.10: Pearson’s Chi-Square Test of Independence to Determine
Association Between Attending Physician and Insurance Plan
Value

df

Asymp. Sig.
(2-sided)

Pearson Chi-Square

.510*

3

.917

Likelihood Ratio

.494

3

.920

Linear-by-Linear
Association

.009

1

.925

N of Valid Cases

154

*. 1 cell (12.5%) has an expected count less than 5. The minimum expected count is
2.28.

Table 4.11: Risk of ACE Inhibitor Prescribed by Insurance Plan
ACE Inhibitor Prescribed
Yes
No
Payor

Total

FFS
HMO

74
28

41
11

115
39

Total

102

52

154

Table 4.12: Risk Estimate of ACE Inhibitor Prescribed by Insurance Plan
Value
Odds Ratio for Payor
(FFS/HMO)
For cohort ACE Inhibitor
Prescribed? = Yes
For cohort ACE Inhibitor
Prescribed? = No
N of Valid Cases

95% Confidence Interval
Lower
Upper

.709

.320

1.570

.896

.706

1.138

1.264

.724

2.208

154
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Results of the odds ratio test revealed no increased risk of follow-up being scheduled
within 2 weeks at time of discharge between the insurance plans. Table 4.14 displays the
results of the risk estimate.
To determine differences in risk of documentation of discharge teaching by insurance
plan, an exposed odds ratio test was performed. Out of an N of 120, the data revealed
44% of FFS cases and 51.7% of HMO cases had complete documentation of discharge
teaching. Table 4.15 displays the distribution of cases. Results of the odds ratio test
revealed no increased risk of documentation of discharge teaching by insurance plan.
Table 4.16 displays the results of the test.

Table 4.13: Follow-up Scheduled within Two Weeks by Insurance Plan
Follow-up scheduled within 2 weeks
following discharge?
Yes
No
Payor

Total

FFS
HMO

100
36

15
3

115
39

Total

136

18

154

Table 4.14: Risk Estimate of Follow-up Scheduled at Discharge by Insurance Plan

Odds Ratio for Payor
(FFS/HMO)
For cohort follow-up
scheduled within two weeks
following discharge? = Yes
For cohort follow-up
scheduled within two weeks
following discharge? = No
N of Valid Cases

Value

95% Confidence Interval
Lower
Upper

.556

.152

2.032

.942

.840

1.057

1.696

.518

5.547

154
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Table 4.15: Documentation of Discharge Teaching by Insurance Plan
Documentation of discharge
teaching?
Yes
No
Payor

Total

FFS
HMO

40
15

51
14

91
29

Total

55

65

120

Table 4.16: Risk Estimate of Discharge Teaching by Insurance Plan
Value
Odds Ratio for Payor
(FFS/HMO)
For cohort documentation
of discharge teaching? =
Yes
For cohort documentation
of discharge teaching? =
No
N of Valid Cases

95% Confidence Interval
Lower
Upper

.732

.317

1.692

.850

.558

1.295

1.161

.764

1.764

120

ANALYSIS OF THE RESEARCH QUESTIONS
The research questions proposed in Chapter 1 are addressed in the following section.
Research Question #1:

How do comparable health outcomes differ for posthospitalized congestive heart failure patients enrolled in
FFS or HMO insurance plans?

Analysis:

The health outcomes assessed to address research question
1 included attending physician, follow-up with health care
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provider scheduled at discharge, and documentation of
discharge teaching. According to the results of this study,
there are no statistically significant differences in health
outcomes between FFS and HMO insurance plans.
Research Question #2:

How do health outcome measurements for posthospitalized congestive heart failure patients enrolled in
and FFS insurance plans affect comparable morbidity
rates?

Analysis:

The health outcomes assessed to address research question
2 included length of stay, readmission within 30 days of
discharge with a related diagnosis, and treated with an ACE
inhibitor. According to the results of this study, no
statistically significant association between morbidity rates
and insurance plan was found. Although shorter LOS and
higher readmission rates for HMO members were revealed,
no statistically significant differences were discovered.

Research Question #3:

How do health outcome measurements for posthospitalized congestive heart failure patients enrolled in
FFS and HMO insurance plans affect comparable mortality
rates?

Analysis:

The health outcome assessed to address research question 3
included mortality rates for each insurance plan. Results
revealed all six cases of mortality in FFS insurance plans;
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however an exposed odds ratio test did not indicate a
statistically significant difference in mortality rates due to
sample size and distribution. All six cases of mortality
were found in patients ages 67 and up. It was also
discovered that an association between being age 67+ and
enrolled in a FFS insurance plan was present.

INTERPRETATION OF THE DATA
The data presented in this study revealed no statistically significant difference in
congestive heart failure health outcomes between FFS and HMO insurance plans. Given
that managed care reimbursement guidelines are more stringent than FFS plans, the
implications of the findings of this study indicate that managed care plans (specifically
HMO plans) do not compromise quality of care in the administration and reimbursement
of health care services for congestive heart failure patients. The sections below discuss
the implications of the findings of this study as they relate to health care providers,
patients, and the health care industry as a whole.
Implications of Findings for Health Care Providers
Based on the findings of this study, the quality of care for congestive heart failure
patients does not vary between FFS and HMO insurance plans. Given the above
findings, the method of reimbursement (specifically FFS or HMO insurance plans) does
not affect the quality of care administered by health care providers. No statistically
significant differences were found by attending physician, therefore physician specialty
(cardiology, family practice, medicine, or other) does not affect the quality of care
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provided for congestive heart failure patients enrolled in FFS or HMO insurance plans.
Based on the above, physicians caring for congestive heart failure patients should not find
significant differences in the health outcomes for those patients enrolled in FFS and
HMO insurance plans.
Implications of Findings for Patients
With approximately 4.7 million cases and an overall 5-year mortality rate of 50% for
congestive heart failure patients (Whellan et al, 1999), the seriousness of this illness is
undisputed. Based on the findings of this study, patients with congestive heart failure
enrolled in FFS and HMO insurance plans should not be affected by payor source in the
quality of care they receive from their insurance plan and more specifically, their health
care providers.
The study revealed a higher percentage of patients ages 67+ enrolled in FFS insurance
plans compared to patients enrolled in HMO insurance plans. The findings are likely
related to the high number of Medicare patients that comprised the FFS group and the
fact that CHF is more prevalent in the elderly population. In addition, Medicare HMOs
are not as prevalent in the East Tennessee area as compared to other areas of the United
States, thereby contributing to decreased numbers of elderly HMO members available for
this study.
Implications of Findings for the Health Care Industry
Given the undisputed fact that heart disease is the number one cause of death in
Americans today with congestive heart failure comprising one of the most costly
diagnosis groups, the payors, patients, and health care providers should not see a
difference in the quality of care provided between congestive heart failure patients
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enrolled in FFS or HMO insurance plans. Nationwide, half of the patients discharged
with a CHF diagnosis return to the hospital within 90 days, revealing the difficulty in
managing the condition (Xuan et al, 2000). The data in this study revealed 22.6% of FFS
cases and 25.6% of HMO cases were readmitted to the hospital within 30 days of
discharge with a related diagnosis, and no statistically significant difference in
readmission rates found between the insurance plans. As indicated in previous studies,
better case management of CHF patients could possibly contribute to decreased
readmission rates and subsequent costs associated with treatments and hospitalizations.
This study revealed HMO patients had a shorter length of stay and 3% higher
readmission rate, possibly indicating that the managed care plans in this study did not
positively affect readmission rates as compared to FFS patients who received no case
management through their insurance plan.

SUMMARY
In summary, no statistically significant difference in health outcome measurements
between FFS and HMO insurance plans was revealed, however differences do exist. The
following chapter will discuss a summary of the findings, conclusions, and
recommendations.
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CHAPTER V
SUMMARY, FINDINGS, CONCLUSIONS, AND RECOMMENDATIONS
INTRODUCTION
This chapter is divided into the following 4 sections: summary of the study, findings
of the study, conclusions, and recommendations.

SUMMARY
The problem addressed in this study determined differences in quality of care as
evidenced by post-hospitalized congestive heart failure health outcomes between FFS and
HMO insurance plans for patients discharged from the University of Tennessee Medical
Center, Knoxville. To accomplish this, the following three research questions were
developed:
1. How do comparable health outcomes differ for post-hospitalized congestive
heart failure patients enrolled in FFS and HMO insurance plans?
2. How do health outcome measurements for post-hospitalized congestive heart
failure patients enrolled in FFS and HMO insurance plans affect comparable
morbidity rates?
3. How do health outcome measurements for post-hospitalized congestive heart
failure patients enrolled in FFS and HMO insurance plans affect comparable
mortality rates?
To achieve the purpose of the study, secondary data were collected from an ongoing
congestive heart failure monitor being implemented at the University of Tennessee
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Medical Center, Knoxville (UTMCK). Original case selection for the UTMCK study
was based on a stratified random sample (by attending physician) of all patients
discharged from UTMCK with a primary diagnosis of CHF. For this study, data were
collected from a total of 154 subjects. The health outcome measurements for this study
obtained from UTMCK's CHF monitor included the following:
1.

Length of stay (days)

2.

Mortality

3.

Gender (male/female)

4.

Payor (FFS/HMO)

5.

Readmitted within 30 days of discharge with related condition

6.

Attending physician (cardiology, medicine, family practice, other)

7.

Treated with ACE inhibitor

8.

Follow-up with a health care provider within 2 weeks scheduled at
discharge

9.

Documentation of instruction (discharge instructions)
A.

Diet

B.

Weight

C.

Medications

D.

Activity level

E.

CHF teaching booklet

In addition to the above health outcome measurements, the type of insurance was
recorded with selection limited to patients enrolled in either a fee-for-service or health
maintenance organization insurance plan.
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Data was analyzed using the following statistical tests. To test the null hypothesis that
average length of stay of FFS members is equal to the average length of stay of HMO
members, an independent sample t-test was performed. A Pearson's chi-square test of
independence was used to determine whether or not the class of attending physician is
dependent upon type of insurance. An exposed odds ratio test was performed to compare
the following outcome data:
1.

Mortality rates

2.

Readmission within 30 days with a related diagnosis

3.

Treated with ACE inhibitor

4.

Follow-up with health care provider scheduled at discharge

5.

Documentation of discharge teaching.

Data was entered into a Microsoft Excel spreadsheet and statistically analyzed using
SPSS version 11.0.

FINDINGS
The data collected and statistical tests used to answer the three research questions
produced the following findings:
1. No statistically significant difference in the length of stay of HMO members
compared to FFS members was found. There was a shorter length of stay
revealed in HMO members with an average of 4.95 days and 5.32 days for FFS
members.
2. Results revealed all six cases of mortality in FFS insurance plans, however an
exposed odds ratio test did not indicate a statistically significant difference in
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mortality rates due to sample size and distribution. All six cases of mortality were
found in patients ages 67 and up. It was also discovered that an association
between being age 67+ and enrolled in a FFS insurance plan was present.
3. With a total of 154 cases, 22.6% of FFS members and 25.6% of HMO members
were readmitted to the hospital within 30 days of discharge with a related
diagnosis. Although HMO members had a 3% higher readmission rate, an
exposed odds ratio did not indicate a significant difference between the insurance
plans.
4. Payor source did not affect the probability of cases being attended by a specialist
during their hospital stay. A Pearson’s chi square test of independence revealed
no greater likelihood of FFS and HMO members being attended by cardiology,
medicine, family practice, or other physician specialty.
5. Payor source did not affect the likelihood of a patient being treated with an ACE
inhibitor. An exposed odds ratio did not reveal a significant difference in the
number of patients treated with an ACE inhibitor between the insurance plans.
6. No significant difference in the number of cases with scheduled health care
provider follow-up within 30 days of discharge was found.
7. No significant difference in cases with documentation of discharge teaching
between the insurance plans was found.

CONCLUSIONS
Based on the findings of this study the following conclusion was drawn:
1. Congestive heart failure patients discharged from the University of
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Tennessee Medical Center, Knoxville enrolled in FFS or HMO insurance
plans do not experience significant differences in quality of care as evidenced
by the health outcomes collected for this study.

RECOMMENDATIONS
Based on the data produced by this study, the following recommendations were made:
1. The study should be replicated in other Knoxville, Tennessee hospitals to provide
data generalizable to the geographic population.
2. Further study into decreased length of stay and higher readmission rates among
HMO insurance plans should be conducted.
3. Investigation into documentation of teaching, follow-up scheduled at discharge,
and the effect on readmission rates could provide data supporting the need for
adequate teaching and follow up to decrease exacerbations and subsequent higher
readmission rates.
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APPENDIX A
CONGESTIVE HEART FAILURE INSTRUMENT

Indicator
Average Age (years)
Average LOS (days)
Median LOS (days)
Mortality
Gender:
• Male
• Female
Payor:
• Medicare
• TN Care
• Blue Cross
• Other
Readmitted within 30 days of this discharge with related
condition
Attending physician:
• Cardiology
• Medicine
• Family Practice
• Other
Cardiology consulted if not attending
Etiology of CHF documented
Cases which had procedure to establish ejection fraction
• MUGA
• PET
• ECHO
• Cath

#

%

Comments

72

Indicator
Ejection fraction:
• < 20 %
• 20 - 30 %
• 31 - 40 %
• > 40 %
No ejection fraction documented, but severe LV
dysfunction noted
ACE Inhibitor
• Cases receiving during hospitalization
• Cases which did not receive ACE inhibitor during
hospitalization
# with absolute contraindication
# with relative contraindication
# with no documented contraindication
• Discharged on ACE if not contraindicated

Beta Blocker
• Cases receiving during hospitalization
•

Discharged on beta blocker if not contraindicated

ASA
• Cases receiving during hospitalization
• Discharged on ASA if not contraindicated
Coumadin
• Cases receiving during hospitalization

#

%

Comments

73

Indicator
ARB
• Cases receiving during hospitalization
Spironolactone
• Cases receiving during hospitalization
Follow-up with a healthcare provider within 2 weeks
scheduled at discharge
Home Care consulted
Documentation of teaching (discharge instructions)
• Diet
• Weight
• Meds
• Activity Level
• CHF Teaching Booklet

#

%

Comments
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APPENDIX B
DISTRIBUTION OF CASES BY AGE AND INSURANCE PLAN
Appendix B: Distribution of Cases by Age and Insurance Plan
Age

Payor
FFS

Total
HMO

19

Count
% within

1
100.0%

1
100.0%

26

Count
% within

1
100.0%

1
100.0%

32

Count
% within

36

Count
% within

37

Count
% within

1
100.0%

1
100.0%

40

Count
% within

1
100.0%

1
100.0%

42

Count
% within

1
50.0%

46

1
100.0%

1
100.0%
1
100.0%

1
100.0%

1
50.0%

2
100.0%

Count
% within

1
100.0%

1
100.0%

48

Count
% within

4
100.0%

4
100.0%

49

Count
% within

2
100.0%

2
100.0%

50

Count
% within

1
25.0%

3
75.0%

4
100.0%

51

Count
% within

2
66.7%

1
33.3%

3
100.0%

53

Count
% within

2
50.0%

2
50.0%

4
100.0%

54

Count
% within

3
75.0%

1
25.0%

4
100.0%
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Appendix B: Distribution of Cases Continued
Age

Payor

Total

FFS

HMO

1
33.3%

2
66.7%

3
100.0%

55

Count
% within

56

Count
% within

1
100.0%

1
100.0%

57

Count
% within

4
100.0%

4
100.0%

58

Count
% within

1
20.0%

4
80.0%

5
100.0%

59

Count
% within

1
33.3%

2
66.7%

3
100.0%

60

Count
% within

100.0%

1
100.0%

1
100.0%

1
100.0%

1
100.0%

1
33.3%

3
100.0%

1
100.0%

1
100.0%

61

Count
% within

62

Count
% within

63

Count
% within

64

Count
% within

2
100.0%

2
100.0%

65

Count
% within

3
100.0%

3
100.0%

66

Count
% within

67

Count
% within

1
100.0%

1
100.0%

68

Count
% within

6
100.0%

6
100.0%

69

Count
% within

3
100.0%

3
100.0%

70

Count
% within

2
100%

2
100%

2
66.7%

1
100.0%

1
100.0%
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Appendix B: Distribution of Cases Continued
Age

Payor
FFS

Total
HMO

71

Count
% within

3
100.0%

3
100.0%

72

Count
% within

6
100.0%

6
100.0%

73

Count
% within

4
100.0%

4
100.0%

74

Count
% within

7
77.8%

75

Count
% within

6
100.0%

6
100.0%

76

Count
% within

1
100.0%

1
100.0%

77

Count
% within

6
100.0%

6
100.0%

78

Count
% within

2
100.0%

2
100.0%

79

Count
% within

2
100.0%

2
100.0%

80

Count
% within

6
85.7%

81

Count
% within

5
100.0%

5
100.0%

82

Count
% within

6
100.0%

6
100.0%

83

Count
% within

2
100.0%

2
100.0%

84

Count
% within

5
100.0%

5
100.0%

85

Count
% within

5
100.0%

5
100.0%

2
22.2%

1
14.3%

9
100.0%

7
100.0%
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Appendix B: Distribution of Cases Continued
Age

Payor
FFS

Total
HMO

86

Count
% within

1
100.0%

1
100.0%

87

Count
% within

2
100.0%

2
100.0%

89

Count
% within

2
100.0%

2
100.0%

90

Count
% within

3
100.0%

3
100.0%

92

Count
% within

2
100.0%

2
100.0%

93

Count
% within

1
100.0%

1
100.0%

94

Count
% within

1
100.0%

1
100.0%

95

Count
% within

1
100.0%

1
100.0%

97

Count
% within

1
100.0%

1
100.0%

98

Count
% within

1
100.0%

1
100.0%

Total

Count
% within

115
74.7%

39
25.3%

154
100.0%
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